MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital Universitario Arnau de Vilanova](/img/noimage_org.png)
Hospital Universitario Arnau de Vilanova
Lleida, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Arnau de Vilanova (24)
2023
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505
2022
-
Cell-Free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions
Annals of the American Thoracic Society
-
Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
Cancers, Vol. 14, Núm. 24
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer
Pleura and Peritoneum, Vol. 6, Núm. 2, pp. 75-81
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
2019
-
Clinical impact of circulating tumor RAS and BRAF mutation dynamics in patients with metastatic colorectal cancer treated with first-line chemotherapy plus anti–epidermal growth factor receptor therapy
JCO Precision Oncology, Vol. 3
-
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy before Standard Chemoradiotherapy and Surgery in Patients with High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
JAMA Oncology, Vol. 5, Núm. 11, pp. 1566-1573
-
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: The ULTRA trial
Annals of Oncology, Vol. 30, Núm. 5, pp. 796-803
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
-
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Oncologist, Vol. 23, Núm. 9, pp. 1092-1102
2017
-
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: Long-term results from the GEMCAD 0801 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 344-353
-
Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases
Histology and Histopathology, Vol. 32, Núm. 9, pp. 909-915
-
Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro
Archivos de Bronconeumologia, Vol. 53, Núm. 8, pp. 427-431
2014
-
A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
Cancer Letters, Vol. 351, Núm. 1, pp. 30-40
-
Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer
Virchows Archiv, Vol. 464, Núm. 6, pp. 645-654
2013
-
Human Papillomavirus in Non-Small-Cell Lung Cancer: The Impact of EGFR Mutations and the Response to Erlotinib
Archivos de Bronconeumologia, Vol. 49, Núm. 2, pp. 79-81
-
Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab
Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452
-
Phase ii study of irinotecan in combination with capecitabine on a 3-weekly schedule as first-line chemotherapy for patients with metastatic or locally advanced colorectal cancer
Journal of Analytical Oncology, Vol. 2, Núm. 3, pp. 151-159